GnRH Agonist Administration in the Luteal Phase of ICSI-ET Cycles

Summary

A single dose GnRH agonist administration in the luteal phase of assisted reproduction cycles was reported to increase pregnancy and birth rates. This study was done to evaluate the reproducibility of previous findings.

Timeline

Start

2006-09

Primary completion

—

Completion

2007-07

Outcome

Missed primary endpoint

paper does not seem to result in an increase >or=12% in ongoing pregnancy rates. PMID 18192671 ↗

paper absolute difference +1.7%, 95% confidence interval -5.8% to +9.2% PMID 18192671 ↗

Publications

• Background Tesarik J, Hazout A, Mendoza-Tesarik R, Mendoza N, Mendoza C. Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles. Hum Reprod. 2006 Oct;21(10):2572-9. doi: 10.1093/humrep/del173. Epub 2006 Aug 22.
• Ata B, Yakin K, Balaban B, Urman B. GnRH agonist protocol administration in the luteal phase in ICSI-ET cycles stimulated with the long GnRH agonist protocol: a randomized, controlled double blind study. Hum Reprod. 2008 Mar;23(3):668-73. doi: 10.1093/humrep/dem421. Epub 2008 Jan 12.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Triptorelin	Other / unclassified	0.1 mg	Subcutaneous

Indications